Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Recruiting · NCT06663111 · Registry updated 2024-10-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rituximab and Ocrelizumab in Serum With Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Not stated | 2024-10-29 | NCT06663111 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Haukeland University Hospital | 163 |
| University of Bergen | 70 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Haukeland University Hospital, Deparment of medical biochemistry and pharmacology | Bergen | Norway | 1 |